ADARx Pharmaceuticals is a clinical-stage biotechnology company developing RNA-based therapeutics using its proprietary ADAR (Adenosine Deaminase Acting on RNA) editing platform. The company is allied with AbbVie and has three drugs in the clinic.
Two RNA biotechs, ADARx Pharmaceuticals and City Therapeutics, are taking advantage of an IPO window that has produced 27 newly public biotechs so far this year, with ADARx raising $446 million.
AbbVie-backed ADARx Pharmaceuticals plans an IPO to fund its clinical-stage siRNA therapy pipeline.
Gene Silencing-Biotech ADARx Makes Some Noise With $535M Stock Market Debut